John D. Hamilton, MD; Michael S. Simberkoff, MD; Pamela M. Hartigan, PhD
To the editors: We read with interest the article by Schulman and colleagues (1). Our major concern about their method is the use of data on time to progression to the acquired immunodeficiency syndrome (AIDS) to make statements about survival. This is an extraordinarily important variable for which almost no data exist. They draw from the randomized AIDS Clinical Trial Group Protocol 019, which had only eight deaths, four in the placebo-treated group and four in the zidovudine-treated group (2).
Zidovudine prolongs survival in human immunodeficiency virus (HIV)-infected patients once they progress to AIDS or to AIDS-related complex (3-5). It
Hamilton JD, Simberkoff MS, Hartigan PM. Cost Effectiveness of Treating Asymptomatic HIV Infection. Ann Intern Med. ;115:655–656. doi: 10.7326/0003-4819-115-8-655
Download citation file:
Published: Ann Intern Med. 1991;115(8):655-656.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use